Jim Cramer's Mad Money In-Depth, 3/10/08: Radio Killed the Radio Star

by: Miriam Metzinger

Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Monday March 10. Click on a stock ticker for more analysis.

The current economic climate is one in which stocks are guilty until proven innocent and investors should strive merely to avoid losing more money than the next guy. The watchword is capital preservation rather than capital appreciation, and Cramer thinks a bottom will come only when a bank rallies, causing customers to panic and withdraw money. Cramer would only consider buying stock in the case of a short rally when stocks oversold, when the negativity is finished, if a company has solid earnings and a catalyst, and if a stock has a dividend of over 4% and double-digit earnings. After researching stocks over the weekend, Cramer found very few names that fit the bill.

Genentech (Private:DNA), Gilead (NASDAQ:GILD)

No one is going to hit a homerun this market, said Cramer, but investors can at least get to first base with DNA. Biotech is usually strong during troubled times and while GILD has led the sector, Cramer says DNA is cheaper and has lower costs, stronger upside potential and more robust growth. Good news on the company’s analyst meeting on Friday could bring the stock up, and Cramer would buy DNA, since he predicts it will rise 28% to $100 in the next year.

Sirius Satellite Radio (NASDAQ:SIRI), XM Satellite (XMSR), Cumulus Media (NASDAQ:CMLS), Clear Channel (NYSE:CLR), Entercom (NYSE:ETM), Saga (NYSEMKT:SGA), Beasley (NASDAQ:BBGI)

Cramer was on the soapbox once again about the delay in the SIRI and XMSR merger and blamed terrestrial radio, an industry that is “falling apart” and National Association of Broadcasters for sabotaging the potential deal. Terrestrial radio companies are clear sells on swiftly declining ad revenues. The average market cap for terrestrial radio has fallen 80% in the last five years.

CEO Interview: Mark Miller, Stericycle (NASDAQ:SRCL)

Cramer praised SRCL which is up 44% in little over a year and is a good investment in a difficult market, since it is impervious to the economic climate; “People don’t decide to get blood tests based on how the market is doing,” Miller said. With the company’s five acquisitions in the last quarter and more growth ahead, Cramer said SRCL is one of the very few stocks he is “very bullish” on.

Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round, Stop Trading and his Wall Street Confidential Picks.

Get Cramer's Picks by e-mail -- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with Jim Cramer, CNBC or TheStreet.com